Levi & Korsinsky, LLP reminds shareholders that a BIIB class action lawsuit has been commenced on behalf of investors who purchased Biogen Inc. (BIIB) securities between October 22, 2019 and November 6, 2019. For more on the Biogen Class Action please contact us today.

According to the Biogen lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(1) the larger dataset did not provide necessary data regarding aducanumab’s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen’s investigational human monoclonal antibody studied for the treatment of early Alzheimer’s disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab’s effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

TO LEARN MORE ABOUT THE BIIB CLASS ACTION, CLICK HERE

If you suffered a loss in Biogen you have until January 12, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery does not require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com